Testing XR:NTX vs XR:B (Sublocade) (035)


Study Information

The New York University (NYU) School of Medicine JCOIN Research Center conducting a large multisite trial to compare the effectiveness of extended-release buprenorphine (Sublocade, XR-B) to extended-release naltrexone (XR-NTX). The trial will enroll individuals prior to release from jail and randomize to either medication option. The first dose of medication will be administered prior to release, with an additional 24 weeks of treatment received in the community.

Participating jails are located in Connecticut, Delaware, New Hampshire, New Jersey, and Oregon. The study will measure retention in treatment, and opioid and other substance use outcomes between the two medication conditions, as well as a sample of individuals who opt for other treatment options (“treatment as usual”).

Study Settings: Jails/Prisons, Treatment/Healthcare Settings

Study Locations: Connecticut, Delaware, New Hampshire, New Jersey, Oregon

Study Team

PI: David Farabee, Elizabeth Waddell, Josh Lee, Lisa Marsch, Robert Schwartz, Sandra Springer

NYU School of Medicine Logo

Study Aims

• Compare the effectiveness of XR-B vs XR-NTX on medication adherence (retention)

• Measure opioid and other substance use outcomes

• Compare study subjects to a treatment-as-usual sample

• Identify implications for the use of long-acting injectable MOUD in justice settings

Research Type

Clinical Trial, MOUD Comparative Effectiveness